Drug intelligence / Profile preview

SBP-105

Development stage: Unknown
Lead developer: SPARK Biopharma
Modality: Small Molecules

Overview

SBP-105 is a small molecule drug developed by Spark BioPharma for the treatment of solid tumors. It acts as an agonist of STING (Stimulator of Interferon Genes), a key component in innate immune signaling pathways that can promote anti-tumor immunity. The drug is classified as an antineoplastic agent and is currently in early research or discovery stages, with no defined orphan drug status or regulatory approvals reported. Its mechanism involves activating the STING pathway to stimulate immune responses against cancer cells[1][2].

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on SBP-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-105.

Explore the full profile